Payment overview · 2025
General Payments
$325.25
21 reported records · 12 companies
Healthcare provider profile · identity verified
Robert Joseph Aertker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CROWLEY, LA · NPI 1780877944
Verified facts
What the public records show
CMS Open Payments records show Robert Joseph Aertker, M.D. received $325.25 in general payments during 2025 across 21 reported records.
ABBVIE INC. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.09 | 22.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.47 | 12.4% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $35.13 | 10.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.04 | 10.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.59 | 7.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.21 | 5.9% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $18.42 | 5.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.19 | 5.6% | 4 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.87 | 5.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.00 | 4.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.28 | 4.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.96 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $325.25 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.93 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.47 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.19 | 4 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
89 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 604 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 494 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 66 |
| Metformin Hcl | Metformin Hcl | 267 | 59 |
| Gabapentin | Gabapentin | 254 | 50 |
| Montelukast Sodium | Montelukast Sodium | 224 | 51 |
| Losartan Potassium | Losartan Potassium | 222 | 42 |
| Lisinopril | Lisinopril | 208 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 57 |
| Sertraline Hcl | Sertraline Hcl | 203 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 37 |
| Atorvastatin Calcium | Atorvastatin Calcium | 195 | 44 |
| Prednisone | Prednisone | 179 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 38 |
| Furosemide | Furosemide | 172 | 46 |
| Famotidine | Famotidine | 162 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 157 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 36 |
| Potassium Chloride | Potassium Chloride | 150 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 35 |
| Ezetimibe | Ezetimibe | 134 | 23 |
| Simvastatin | Simvastatin | 133 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 23 |
| Allopurinol | Allopurinol | 128 | 26 |
| Eliquis | Apixaban | 123 | 24 |
| Buspirone Hcl | Buspirone Hcl | 122 | 31 |
| Carvedilol | Carvedilol | 122 | 30 |
| Januvia | Sitagliptin Phosphate | 119 | 25 |
| Trazodone Hcl | Trazodone Hcl | 112 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 29 |
| Meloxicam | Meloxicam | 107 | 37 |
| Metformin Hcl Er | Metformin Hcl | 107 | 23 |
| Glimepiride | Glimepiride | 106 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 15 |
| Tramadol Hcl | Tramadol Hcl | 96 | 27 |
| Alendronate Sodium | Alendronate Sodium | 95 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 35 |
| Warfarin Sodium | Warfarin Sodium | 91 | 11 |
| Synthroid | Levothyroxine Sodium | 89 | 11 |
| Cefdinir | Cefdinir | 86 | 59 |
| Memantine Hcl | Memantine Hcl | 86 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 26 |
| Valsartan | Valsartan | 81 | 18 |
| Glipizide | Glipizide | 78 | 14 |
| Donepezil Hcl | Donepezil Hcl | 74 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 19 |
| Alprazolam | Alprazolam | 68 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Lactulose | Lactulose | 55 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 13 |
| Bupropion Hcl | Bupropion Hcl | 52 | 13 |
| Azithromycin | Azithromycin | 51 | 39 |
| Clonazepam | Clonazepam | 51 | 12 |
| Clonidine Hcl | Clonidine Hcl | 51 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 50 | 48 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 38 |
| Finasteride | Finasteride | 47 | 16 |
| Lamotrigine | Lamotrigine | 47 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 25 |
| Nystatin | Nystatin | 41 | 11 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Estradiol | Estradiol | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 17 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Mupirocin | Mupirocin | 34 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Clotrimazole | Clotrimazole | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Humalog | Insulin Lispro | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 26 | 24 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 11 |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 11 |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 13 | 12 |
| Celecoxib | Celecoxib | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $325.25 · 21 records | ABBVIE INC. | BREZTRI, CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, EVKEEZA, GARDASIL 9, IBSRELA, MOUNJARO, Ozempic, QULIPTA, Qelbree, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN FLX, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error